Recent Updates
Recently added Catalysts
RAPP

Rapport Therapeutics Appoints Chief Financial Officer

Monday, October 30, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rapport Therapeutics Appoints Chief Financial Officer

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+91%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
RAP-219
Phase 3 · Focal Seizure

Full Press Release Details

Rapport Therapeutics Appoints Chief Financial Officer.
ShareAdd on Google
Tags: RAPP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 30, 2023

Biotech snapshot

Cash runway
$436M liquidity · $14M/mo burn
~31 mo
Minimal dilution risk
Lead asset
RAP-219Phase 3
Focal Seizure →

Catalyst track record

+91%
best trade around RAPP's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RAPP.

See every catalyst's timing & PoA →